Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
$9.20
$9.63
$8.06
$18.75
$122.99M1.6946,655 shs27,955 shs
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
$2.57
+4.5%
$3.59
$1.80
$7.93
$112.26M0.23233,543 shs69,108 shs
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$0.52
-1.0%
$0.85
$0.46
$4.37
$29.90M0.25700,711 shs274,233 shs
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
$3.17
+1.0%
$3.49
$1.60
$10.48
$122.31M1.34774,914 shs134,742 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
0.00%-4.76%-5.54%-24.65%-37.67%
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
0.00%-12.46%-37.24%+1.65%+245,999,900.00%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
0.00%-6.20%-18.00%-65.89%-86.97%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
0.00%-5.99%-1.57%-28.96%+22.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
2.2356 of 5 stars
3.51.00.00.02.73.30.0
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.1061 of 5 stars
3.51.00.00.02.71.70.6
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
2.4523 of 5 stars
3.62.00.00.03.50.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
3.00
Buy$39.00319.81% Upside
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
3.25
Buy$12.67390.01% Upside
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
3.00
Buy$7.331,323.95% Upside
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3.14
Buy$20.50549.76% Upside

Current Analyst Ratings Breakdown

Latest RANI, GLSI, TARA, and HURA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$21.00
5/16/2025
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
5/16/2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$14.00 ➝ $4.00
4/28/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00
4/21/2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$38.00 ➝ $39.00
4/16/2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$12.00
4/3/2025
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$13.00 ➝ $12.00
4/3/2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/A$0.52 per shareN/A
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/A($4.11) per shareN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
$1.20M24.67N/AN/A$0.51 per share1.01
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/A$6.01 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
-$8.32MN/A0.00N/AN/AN/A-152.88%N/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$33.97M-$0.99N/AN/AN/AN/A-219.64%-56.71%8/5/2025 (Estimated)
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$40.42M-$1.72N/AN/AN/AN/A-55.96%-49.06%8/5/2025 (Estimated)

Latest RANI, GLSI, TARA, and HURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2025Q1 2025
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.24-$0.25-$0.01-$0.25N/AN/A
5/15/2025Q1 2025
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
-$0.13-$0.15-$0.02-$0.15N/AN/A
5/13/2025Q1 2025
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.22-$0.22N/A-$0.22N/A$0.20 million
5/8/2025Q1 2025
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
-$0.47-$0.29+$0.18-$0.29N/AN/A
4/15/2025Q4 2024
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
-$0.21-$0.61-$0.40-$0.61N/AN/A
3/31/2025Q4 2024
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
-$0.24-$0.27-$0.03-$0.27N/A$1.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/AN/AN/AN/AN/A
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/AN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
N/AN/AN/AN/AN/A
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
N/A
6.91
6.91
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
N/A
1.54
1.54
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
2.34
1.60
1.60
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
N/A
9.85
9.85

Institutional Ownership

CompanyInstitutional Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
4.16%
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
0.62%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
30.19%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
38.13%

Insider Ownership

CompanyInsider Ownership
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
51.67%
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
0.20%
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
50.42%
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
8.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Greenwich LifeSciences, Inc. stock logo
GLSI
Greenwich LifeSciences
313.37 million6.35 millionNot Optionable
TuHURA Biosciences stock logo
HURA
TuHURA Biosciences
N/A43.68 million42.20 millionN/A
Rani Therapeutics Holdings, Inc. stock logo
RANI
Rani Therapeutics
11057.48 million26.75 millionOptionable
Protara Therapeutics, Inc. stock logo
TARA
Protara Therapeutics
3038.58 million18.05 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Forecasts TARA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Greenwich LifeSciences stock logo

Greenwich LifeSciences NASDAQ:GLSI

$9.20 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$9.19 -0.01 (-0.11%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

TuHURA Biosciences stock logo

TuHURA Biosciences NASDAQ:HURA

$2.57 +0.11 (+4.47%)
Closing price 04:00 PM Eastern
Extended Trading
$2.56 -0.01 (-0.39%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Rani Therapeutics stock logo

Rani Therapeutics NASDAQ:RANI

$0.52 -0.01 (-0.99%)
Closing price 04:00 PM Eastern
Extended Trading
$0.52 +0.00 (+0.17%)
As of 04:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Protara Therapeutics stock logo

Protara Therapeutics NASDAQ:TARA

$3.17 +0.03 (+0.96%)
Closing price 04:00 PM Eastern
Extended Trading
$3.17 0.00 (0.00%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.